| |
|
|
|
|
|
|
| |
About
Logos Technologies Inc. |
|
Logos Technologies Inc is a leading provider of world-class
clinical trial solutions to pharmaceutical, biotechnology and clinical research organisations.
ALPHADAS® is a proactive eSource clinical trials system that is mobile, schedule-driven,
and provides real-time bedside or station based direct data capture.
It meets the changing demands and time sensitive nature of early phase trials
while integrating with clinical and laboratory operations.
It accelerates data throughput, and enhances data integrity.
|
|
| |
About CNS Network |
|
CNS Network is Southern California’s leading clinical research organization,
specializing in the testing of new medications and treatments for disorders
of the central nervous system such as Schizophrenia, Bipolar disorder, depression,
insomnia, and various neurological disorders such as Alzheimer’s Disease, migraines, and epilepsy.
|
|
|
|
|
|
|
|
|
|
|
|
CNS Network selects ALPHADAS®, Logos Technologies Early Phase EDC System
|
|
|
|
|
London, 17th March 2010
It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.
|
|
|
“We welcome CNS Network as our most recent client partner and look forward to seeing them reap the tremendous rewards that ALPHADAS will bring them” said Giles Wilson, BEng, CEO of Logos Technologies Inc. “Providing real-time reporting and review to their clients and Sponsors was an important requirement and through this partnership we look forward to life changing and life saving drugs reaching the market safely and more quickly.”
CNS Network is a leading independent research organization located in the greater Los Angeles metropolitan market. They conduct phase I-III clinical trials and specialize in early phase trials for disease populations. They are finishing construction of their 25,000 square foot, state-of-the-art facility and have decided to incorporate the ALPHADAS early phase unit automation product. They evaluated several other products in the sector and chose ALPHADAS because of its depth of product functionality and the experience of Logos Technologies. CNS Network CEO, Dr. David Walling states “Through the combination of this automation and the recruitment abilities of CNS Network we believe that we will have a significant advantage over other early phase research organizations in our capacity to deliver clean, easily accessible, timely data to sponsors.”
|
|
After a challenging 2009 for many organizations, 2010 has started well for Logos, having signed four new contracts in the past few months. ALPHADAS, an e-Source, pro-active EDC system which has had great success in early phase clinical trials, is a market proven solution. Other systems may claim to be similar to ALPHADAS, however, none come close to providing the depth of functionality or experience. Even at the top of its’ market Logos continues to invest in ALPHADAS. Over the past 9 months enhancements include further increasing performance for larger or multiple simultaneous studies, plus additional functionality to WebDAQ™ (the ALPHADAS WebPortal), as well as to its online review and reporting tools which provide Sponsors with real-time review of site collected data.
|
| |
For more informtion contact Angela King
angela.king@logostechnologies.com
or visit www.logostechnologies.com
|
|
| |
|
|
|
|
 |
